PatentsGlobal
Erasca Inc. Hit with Securities Class Action Following Patent Dispute and Patient Death, Market Value Drops $2.8 Billion
Erasca, Inc. faces a securities class action lawsuit after its stock plummeted 48% due to allegations of patent infringement by Revolution Medicines and the death of a patient treated with Erasca’s investigational drug ERAS-0015. The suit claims Erasca misled investors about the drug’s intellectual property protection…
Tuesday, June 16, 2026